{"id":60382,"date":"2024-02-28T06:46:37","date_gmt":"2024-02-28T06:46:37","guid":{"rendered":"https:\/\/medsname.com\/quinin-300\/"},"modified":"2026-04-30T10:23:48","modified_gmt":"2026-04-30T10:23:48","slug":"quinin-300","status":"publish","type":"product","link":"https:\/\/medsbase.com\/el\/quinin-300\/","title":{"rendered":"Quinin 300"},"content":{"rendered":"

<\/p>\n

\n

\u0393\u03c1\u03ae\u03b3\u03bf\u03c1\u03b7 \u03b1\u03c0\u03ac\u03bd\u03c4\u03b7\u03c3\u03b7<\/h3>\n

Quinin 300<\/strong> \u03c0\u03b5\u03c1\u03b9\u03ad\u03c7\u03b5\u03b9 quinine sulfate 300 mg<\/strong> (East African Pharmaceuticals (or generic 300 mg)). It is a second-line oral treatment for chloroquine-resistant uncomplicated P. falciparum malaria<\/strong> \u2014 historically combined with doxycycline, tetracycline, or clindamycin to shorten treatment and reduce recrudescence. Modern WHO guidance prefers artemisinin combination therapy (ACT)<\/strong> where available; quinine remains in selected use where ACTs are unavailable, contraindicated, or have failed. Standard treatment dose: 650 mg every 8 hours for 3\u20137 days<\/strong> with doxycycline 100 mg BID for 7 days. Side-effect cluster (“cinchonism” \u2014 tinnitus, headache, nausea, dizziness, blurred vision) is common and dose-limiting. NOT for restless legs cramping<\/strong> (FDA black-box warning since 2010 for that off-label use). Do NOT use without medical supervision.<\/p>\n<\/div>\n

\ud83c\udfed WHO-GMP certified manufacturer<\/strong>  \u00b7  \ud83d\udce6 Discreet packaging<\/strong>  \u00b7  \ud83c\udf0d Worldwide shipping<\/strong>  \u00b7  \u2b50 1,400+ \u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ad\u03c2 \u03c0\u03b5\u03bb\u03b1\u03c4\u03ce\u03bd<\/a><\/strong><\/div>\n

\ud83d\udee1\ufe0f Every order is covered by our \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/strong><\/a> \u2014 if your parcel does not arrive within 20 business days we ship a free replacement on EMS or ITPS courier.<\/p>\n

\u0393\u03b9\u03b1\u03c4\u03af \u03bd\u03b1 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03af\u03bb\u03b5\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b7 MedsBase<\/h3>\n

Quinin 300 is sourced from a WHO-GMP certified manufacturer and shipped worldwide in discreet packaging. Every order is backed by our \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/a> and supported by our 1,400+ \u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ad\u03c2 \u03c0\u03b5\u03bb\u03b1\u03c4\u03ce\u03bd<\/a>. Worldwide shipping with no prescription paperwork.<\/p>\n

About Quinin 300<\/h2>\n

Quinin 300 is a 300 mg quinine sulfate tablet manufactured by East African Pharmaceuticals (or generic 300 mg) under WHO-GMP certified conditions. Quinine is the original antimalarial \u2014 extracted from the bark of the South American cinchona tree by Jesuit missionaries in the 17th century, isolated in pure form by Pelletier and Caventou in 1820, and the standard malaria treatment for the next 100 years before chloroquine. It remains on the WHO Essential Medicines list for second-line P. falciparum treatment and as IV therapy for severe malaria where IV artesunate is unavailable.<\/p>\n

Modern role.<\/strong> WHO and most national guidelines now recommend artemisinin combination therapy (ACT \u2014 artemether-lumefantrine, dihydroartemisinin-piperaquine, artesunate-amodiaquine) as first-line for uncomplicated P. falciparum malaria because ACTs clear infections faster, are better tolerated, and reduce recrudescence. Quinine remains a valid second-line option where ACTs are unavailable, contraindicated, or have failed, in pregnancy first trimester (where ACT data are limited), and intravenously for severe malaria where IV artesunate is unavailable.<\/div>\n
Restless-legs-syndrome warning.<\/strong> Quinine has been used historically for nocturnal leg cramps and restless legs syndrome \u2014 the FDA issued a black-box warning in 2010 against this off-label use<\/strong> after fatal arrhythmia, severe thrombocytopenia, and haemolytic-uraemic syndrome were reported. The risk-to-benefit ratio is unacceptable for a non-malarial indication. Quinin 300 is for malaria treatment only<\/strong> \u2014 not for cramps or restless legs.<\/div>\n

How quinine works<\/h2>\n

Quinine is a cinchona alkaloid that interferes with parasite haem detoxification in the food vacuole \u2014 the same mechanism family as chloroquine and mefloquine. It is active against blood-stage P. falciparum (including most chloroquine-resistant strains), P. vivax, P. ovale, and P. malariae. It does NOT clear dormant hypnozoites \u2014 primaquine is needed for radical cure of vivax \/ ovale.<\/p>\n

Quinine has a short half-life (~ 11 hours) \u2014 three-times-daily dosing is needed during treatment courses. It has a narrow therapeutic window: efficacy is dose-related, but so is toxicity (cinchonism, hypoglycaemia, QT prolongation, rare cardiotoxicity).<\/p>\n

\u0395\u03bd\u03b4\u03b5\u03af\u03be\u03b5\u03b9\u03c2 \u03ba\u03b1\u03b9 \u03b4\u03bf\u03c3\u03bf\u03bb\u03bf\u03b3\u03af\u03b1<\/h2>\n
\n\n\n\n\n\n\n\n\n
\u0395\u03bd\u03b4\u03b5\u03af\u03be\u03b5\u03b9\u03c2<\/th>\n\u0394\u03cc\u03c3\u03b7<\/th>\n\u03a3\u03b7\u03bc\u03b5\u03b9\u03ce\u03c3\u03b5\u03b9\u03c2<\/th>\n<\/tr>\n<\/thead>\n
Uncomplicated chloroquine-resistant P. falciparum malaria, adult<\/td>\n650 mg PO every 8 h for 3 days (Africa) or 7 days (Southeast Asia)<\/td>\nCombine with doxycycline 100 mg BID for 7 days, or clindamycin 20 mg\/kg\/day in pregnancy.<\/td>\n<\/tr>\n
Severe malaria, hospital IV (where IV artesunate unavailable)<\/td>\n20 mg\/kg loading over 4 h \u2192 10 mg\/kg every 8 h IV<\/td>\nCardiac monitoring + glucose monitoring mandatory. Switch to oral 650 mg q8h once tolerated.<\/td>\n<\/tr>\n
Babesiosis (B. microti \/ B. divergens) \u2014 second-line<\/td>\n650 mg q6\u20138h with clindamycin or atovaquone-azithromycin<\/td>\nSpecialist tick-borne disease context.<\/td>\n<\/tr>\n
Paediatric uncomplicated P. falciparum (\u2265 6 kg)<\/td>\n8.3 mg\/kg every 8 h for 3\u20137 days<\/td>\nWith weight-appropriate doxycycline (\u2265 8 years) or clindamycin (any age).<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
Cinchonism \u2014 common and dose-limiting.<\/strong> Most patients on therapeutic-dose quinine develop cinchonism<\/strong> \u2014 a syndrome of tinnitus, mild hearing loss, headache, nausea, dizziness, and blurred vision. The ringing tinnitus and high-frequency hearing loss are the most reliable early sign. Cinchonism does not mandate stopping the drug at mild severity, but signals therapeutic-range plasma levels. Severe cinchonism (deafness, vertigo, severe nausea, mental change) warrants dose review.<\/div>\n
Cardiac and hypoglycaemia red-box.<\/strong> Quinine prolongs QTc and can cause severe hypoglycaemia<\/strong> by stimulating pancreatic beta-cell insulin release \u2014 both effects are amplified at IV dosing and in pregnancy. Hospital IV use requires continuous cardiac monitoring + frequent finger-stick glucose. Avoid combination with other QT-prolonging drugs (azithromycin, ondansetron, antipsychotics, fluoroquinolones, methadone). Severe sudden hypoglycaemia is a medical emergency \u2014 give glucose IV.<\/div>\n

\u03a0\u03b1\u03c1\u03b5\u03bd\u03ad\u03c1\u03b3\u03b5\u03b9\u03b5\u03c2<\/h2>\n